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Summary Flavone acetic acid (FAA) was administered at a dose of 4.8 gm2 over 1 h to patients with
advanced malignant disease in combination with Interleukin II. A new high performance liquid chromato-
graphy method is described to determine both the parent compound and eight drug-related products, and the
conditions required to determine these components in plasma are discussed. The half-life over the first 8 h was
2.3 h, but the terminal clearance of the drug was extremely slow. Severe (WHO Grade 4) hypotension was
observed in some patients. However, incidence of this did not appear to be associated with any differences in
FAA plasma concentrations, nor were there differences in FAA clearance between those patients whose
tumour responded to the drug combination and those who did not.
Flavone acetic acid (FAA) is a flavonoid which has been
found to have high activity against solid murine tumours
(Plowman et al., 1986), although it is inactive against
leukaemias and is not directly cytotoxic in vitro (Bibby et al.,
1987). In a murine renal carcinoma model, it has been shown
to have a synergistic antitumour effect when combined with
Interleukin 2(rIL-2) (Wiltrout et al., 1988), which may
indicate an involvement of immune effector cells. However, it
is possible that metabolism of FAA is required for its action,
and Chabot et al. (1989) have reported the occurrence of
cytotoxic metabolites of FAA. A phase I trial of weekly 1 h
infusions of FAA combined with 5 day infusions of recom-
binant human rIL-2 has been performed, and this paper
describes the effect of rIL-2 on FAA metabolism and inves-
tigates whether the toxicity observed correlates with any
changes in FAA pharmacokinetics or metabolism. A new
HPLC method for the measurement of FAA and its
metabolites is also presented, since published methods (Bibby
et al., 1987; Chabot et al., 1989; Chabot & Gouyette, 1991;
Cummings et al., 1988; Damia et al., 1990; Kerr et al., 1987)
do not resolve adequately all the peaks which we have
observed. This technique enables us to measure FAA, its
glucuronide, seven degradation products, and a minor prod-
uct which we have been unable to characterise further. The
clinical data, histology of post treatment tumour biopsy sam-
ples, nitrate levels and cytokine responses will be presented
separately.
Materials and methods
All chemicals were from BDH Ltd. except for methanol,
acetonitrile and tetrahydrofuran (Rathburn Chemicals Ltd.),
hesperetin (Sigma) and tetrabutyl ammonium hydroxide
(TBA) (Fisons Ltd.).
Fifteen patients with metastatic melanoma were entered
into the trial of FAA (Lipha Lyonnaise Industrielle, Lyons,
France), combined with rIL-2 (Proleukin, Eurocetus, Amster-
dam, Netherlands). Prior to treatment, all patients had pro-
gressive disease and a performance status <3 on a 5-grade
scale according to WHO criteria. The treatment protocol,
which had been approved by the local ethical committee on
human experimentation, was modified during the trial to
reduce the severity of side effects (i.e. hypotension). The first
eight patients were given FAA (4.8 g m-2) as a 1 h infusion
in 500 ml 0.9% saline without urine alkalinisation on days 1,
8 and 15 (courses la, b, c). rIL-2 (6-18 x 106 international
unitsm2day-1) was given as a continuous infusion on days
8-12 and 15-19. For the next seven patients, FAA and IL-2
were given as described except that rIL-2 was given on days
8-12 only. Following treatment, patients were assessed for
clinical responses according to standard WHO criteria and
the treatment was repeated after 2 weeks (courses 2a, b, c)
unless evidence of disease progression was observed.
Blood samples were collected into heparinised tubes and
immediately cooled on ice prior to centrifugation at 4°C. The
samples were then stored at -70°C, normally within 1 h of
sampling. To avoid prolonged thawing times, in the latter
half of the trial, plasma samples were aliquoted into tubes
ready for extraction prior to freezing. For analysis, to 100 gl
(200 rd,> 12 h post FAA) plasma was added 100 nmol
hesperetin (1 mM in methanol), 1 ml methanol, and 50 ll1IM
ammonium acetate pH5.5, and the samples mixed after each
addition. After centrifugation at 4°C, the sample was ready
for analysis by HPLC using a Waters 840 data analysis
system with a WISP autosampler, a Novapak C18 column
(15 cm x 4 mm), and a 441 detector operating at 313 nm.
Most of the separations were carried out using two solvents:
A: 5 mM TBA, 20 mM sodium dihydrogen orthophosphate
(pH6.5); B: 60% acetonitrile, 10% tetrahydrofuran, 30%
water, with linear gradients of 25-34% B, 0-9 min,
34-60%B, 9-15 min, 60-25%B, 15-16 min. The flow rate
was 1.5 ml min-' and the run time 20 min. The low pH
eluent was: A: 5 mM sodium acetate, 0.5 ml 1' glacial acetic
acid (pH4.4); B: 40% acetonitrile, 10% tetrahydrofuran,
50% methanol, with a linear gradent of 15% -30% in 6 min
(Hawarth, 1993; O'Reilly, 1993; Thomsen, 1992).
Results
Chromatography
A chromatogram of a human plasma sample taken 4 h after
the start of infusion of FAA is shown in Figure 1, and
illustrates the large number of drug-related peaks resolved.
The first peak is labelled Ml + M2 since it does in fact
comprise two components. This is shown in Figure 2 where
the peak has been collected and injected into the low pH
eluent, which resolves it into two peaks. The stability of the
main metabolite M4 was also studied under various condi-
tions following collection of the peak. At pH6.5 (th pH of
the eluent), after 20 h at room temperature, -40% of the
peak was lost, with the majority going to M5 - 8 and a small
amount converted back to FAA. Incubation with P-
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Figure 2 HPLC chromatogram of the peak designated Ml ± M2
in Figure 1, collected and analysed using the low pH (acetate,
pH4.4) eluent.
glucuronidase at pH5.0 for 5 min at room temperature
resulted in almost complete conversion to FAA. Other FAA-
related peaks were not susceptible to glucuronidase attack.
At pH2.0, M4, the glucuronide, was stable over 20 h at room
temperature.
Incubation of peaks M5-8 at pH9.0 led to conversion
back to FAA, while similar treatment of Ml + M2 yielded
both M5-8 and FAA. However, Ml + M2 was not seen as a
product of either M4 or M5-8 when incubated alone, only
being detected following incubation of whole plasma or
urine. It did not prove possible to isolate specifically the
individual peaks corresponding to M5-8. This was due in
part to the lack of separation; however, when M5 was col-
lected, re-analysis always showed an equal amount of M8.
M6 and M7 appeared similarly interconvertible, while on
incubation at pH6.5, M5 and M8 appeared to convert par-
tially to M6 and M7.
M9 was observed only at low levels when samples were
analysed immediately following extraction, but increased with
time after extraction, paralleling a decrease in M4.
In the mouse, after a dose of 200 mgkg-' i.p., we found
an essentially identical pattern of products, but the extent of
metabolism was much less. Perhaps because of this, it was
not possible to detect the very minor product M3, which
differs in retention time by less than 0.5 min from both FAA
and M4. If mouse plasma was collected and analysed
immediately, then only small amounts of the other peaks
were seen (Figure 3a). After 24 h at 20°C, M4 was completely
absent and Ml + M2 and M5-8 were seen in approximately
equal proportions (Figure 3b).
Human pharmacokinetics
We have measured FAA and its metabolites in patients
receiving FAA as a 1 h i.v. infusion either before or after
IL-2. The total metabolites were calculated by summing the
areas for all the drug-related peaks other than FAA, assum-
ing an identical extinction coefficient to FAA. Figures 4a and
4b show the plasma concentrations over five courses of FAA
for two patients, one of whom showed a complete tumour
response to the drug combination and one who did not,
while Figure 5 shows the plasma FAA data for all patients
(three responders, 12 non-responders). Concentrations of
FAA measured within 30 min of the end of infusion were
between 285 and 525lagml-'. The clearance was biphasic,
with a half-life over the first 8 h of 2.3 ± 0.15 h (s.e.), cal-
culated by non-linear regression analysis, while the AUC
over 24 h, calculated using the trapezium rule on those
patients where a minimum of five plasma samples were
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Figure 3 HPLC chromatograms of methanol extracts of mouse plasma, 30 min after a dose of 200 mg kg-' i.p. a, extracted and
analysed immediately b, extracted after 24 h at 20°C.
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Figure 4 Plasma concentrations of FAA (open symbols) and total metabolites (closed symbols) in two patients over five infusions
of FAA a, Responder b, Non-responder. 0, *: course la; 0, 0: course Ib; A, A: a, course 2a; b, course Ic; V, V: a, course 2b;
b, course 2a; O, *: a, course 2c; b, course 2b.
obtained, was 2370 ± 130 (Lg ml-') h (s.e.). There appeared
to be no significant changes in the kinetics of FAA clearance
or glucuronide production during the course of treatment,
nor differences between those patients who responded to
treatment and those who did not. However, the responder in
Figure 4, who was one of only four patients to receive five or
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Figure 5 Plasma concentrations of FAA measured in a maximum of five infusions over 1 h. A Responder (three patients); 0 -
Non-responders (12 patients). The line is an exponential fit to all the data to 9 h.
more courses of FAA, and the only one for whom we have
pharmacokinetic data covering the whole treatment schedule,
did appear to show more rapid initial clearance of FAA in
course 2c following her second infusion of IL-2. The main
toxicity observed was that of hypotension, and we have
investigated whether this was related to the plasma FAA
concentration. Figure 6 shows the maximum WHO grade of
hypotension observed for each course plotted against the
concentration of FAA at 2 h after the start of infusion. There
was no correlation between these two parameters: a line fitted
to the data had a slope which did not differ significantly from
zero.
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Figure 6 WHO grade of hypotension and plasma FAA concent-
ration 2 h after the start of infusion.
Discussion
Previous methods for the analysis of FAA have relied on
extraction into an organic solvent such as chloroform
(Damia et al., 1990; Kerr et al., 1987; Staubus et al., 1987) or
the use of solid phase extraction columns (Cummings et al.,
1988). Both of these techniques may result in loss of polar
metabolites which, in the absence of pure standards, may be
difficult to quantify. Because the concentration of FAA is
relatively high at the doses used, we chose a very simple
protein precipitation technique using methanol, following
addition of ammonium acetate, pH5.5 to improve stability of
the metabolites (Cummings et al., 1988). In order to achieve
the separation of the products seen in both the mouse and
man by HPLC, we also found a solvent gradient to be
essential. For this reason, we chose to use hesperetin as
internal standard rather than hesperidin, since the latter
elutes rather close to the drug-related peaks, and the more
hydrophobic hesperetin was readily eluted by the gradient.
Use of the ion-pairing reagent TBA, coupled with a relatively
high pH6.5, enabled us to achieve the best separation apart
from Ml + M2. Initially, we experimented with lower pH
eluents without ion-pairing, using acetate, similar to those
previously described (Cummings et al., 1988), but despite the
improved resolution of MI + M2, overall the separation was
less satisfactory.
The stability studies extend those of Cummings et al.
(1989) and more particularly the recent work of Chabot and
Gouyette (1991), although the latter reported only two prod-
ucts. The peaks M5-8 are presumably the rearrangement
products of the glucuronide as described by Chabot,
although we detected four discrete peaks, in addition to
MI + M2, the latter apparently also being related to the
glucuronide, since high pH incubation (pH9.0) results in the
appearance of the glucuronide-related M5-8. However, the
conditions necessary for the formation of M1 + M2 remain
unclear since they were only produced in the presence of
plasma. M9 is presumably the FAA methylester formed by
the reaction of methanol with the glucuronide as described
by Chabot and Gouyette (1991). This is a potentially serious
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source of error in determining the original glucuronide con-
centration if this peak is not eluted during an isocratic
separation. Because it has an identical absorption spectrum
to the glucuronide (Chabot & Gouyette, 1991), the original
concentration can be determined by summing the individual
components. We also experimented with the use of acetonit-
rile as the protein precipitant instead of methanol. This
competely eliminated the problem of ester formation, but
gave slightly lower recovery of FAA (-85%) compared to
methanol (- 100%).
Although it would appear that the glucuronide M4 is the
only true metabolite of FAA produced in either man or the
mouse, the rearrangement products are almost certainly
formed in vivo since we could never measure just M4 alone,
even if the blood samples were immediately cooled, spun,
extracted and analysed within 30 min of sampling, although
further interconversion undoubtedly takes place if samples
are not processed quickly.
The half-life of 2.3 h, measured in patients over the first
8 h following 4.8 g m-2 FAA, was very similar to that
observed by Kerr et al. (1987). After 8 h, elimination of FAA
from plasma appeared to be slower but we have not attempt-
ed to calculate a rate constant since there were insufficient
data points between 8 h and 20 h. However, fitting the data
in a similar way to that of Kerr et al. (1987) between 8-24 h
would give a half-life of approximately 4 h, comparable to
the 4.1 h reported by these workers. Limited data which we
have for later time points support the observation of Damia
et al. (1990), who showed very slow clearance with a terminal
half-life ofup to 24 h. Differences in the pharmacokinetics do
not appear to predict the response to the combination of
FAA and IL2, nor the incidence of toxicity; this may instead
depend on the cytokine or nitric oxide response of the indi-
vidual patient.
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